Spondyloenchondrodysplasia (SPENCD) with immune dysregulation (SPENCDI) is a rare
autosomal recessive inherited immuno-osseous dysplasia characterized by
spondylo-metaphyseal enchondromas, along with immune dysregulation ranging from
immunodeficiency to autoimmune disorder. Here, we present two cousins with
ACP5 gene mutation who had severe short stature with mild
hypogammaglobulinemia, nephrotic syndrome, autoimmune thyroiditis and cerebral
calcification (Case 1); and in the other (Case 2), there was no clinical
findings other than severe short stature, CD4+−T cell
lymphopenia and non-autoimmune compensated hypothyroidism. We wanted to
emphasize that monogenic causes should be considered in the etiology of
early-onset nephrotic syndrome due to the detection of a mutation in the
ACP5 gene (her actual diagnosis was changed to SPENCDI.) 5 years
after the diagnosis of nephrotic syndrome in the first case, and that the renal
involvement may occur without SLE in patients with ACP5 mutation. Severe
short stature was a common finding in both cases. We underlined that the clinic
can be different even in the same mutation, due to the absence of cerebral
calcification and renal involvement in the second case, which is a cousin with
Case 1. As a result, endocrinologists, immunologists, rheumatologists,
nephrologists and orthopedists should be aware of this syndrome, because SPENCDI
causes a pleiotropic (due to more than one phenotypic effect of a gene) clinical
picture. Severe short stature may be the only presenting sign of patients with
SPENCDI. In addition, in the presence of early-onset nephrotic syndrome and
autoimmune thyroiditis, the patient should be evaluated for this type of
monogenic disorders as well.